| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 14 Nov 2026 | 6 Nov 2026 |
| ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 inter alia to consider and approve Unaudited Financial Results for the quarter and half year ended September 30 2026. | ||
| Board Meeting | 7 Sep 2026 | 7 Sep 2026 |
| This is to inform you, pursuant to Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the Board of Directors of the Company, at its meeting held today, i.e., Monday, September 07, 2026, inter alia, has taken the following decisions:- 1. The Board of Directors of the Company have considered and approved the Report of Board of Directors for the financial year ended as on March 31, 2026 under section 134 of the Companies Act, 2013. 2. The Board of Directors of the Company have considered and approved the Notice of 20th Annual General Meeting of the Company. 3. The Board has approved the day, date, time and calendar of events and Notice of 20th Annual General Meeting of the company to be held on 30th September, 2026 at 12:00 noon, through Video Conferencing (VC)/Other Audio Visual Means (OAVM) * other details as per attachment | ||
| Board Meeting | 14 Aug 2026 | 7 Aug 2026 |
| ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30 2026. Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations, 2015 (As Per BSE Announcement Dated on:14.08.2026) | ||
| Board Meeting | 30 May 2026 | 22 May 2026 |
| ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve the Standalone & Consolidated Audited Financial Results for the 4th Quarter and Financial Year Ended March 31 2026. Audited Financial Results for the quarter and year ended 31st March, 2026 (As Per BSE Announcement Dated on: 30/05/2026) | ||
| Board Meeting | 14 Feb 2026 | 5 Feb 2026 |
| ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended on 31st December 2025. Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025 (As Per BSE Announcement Dated on: 14/02/2026) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.